Autopsy report · NCT05171049
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
Cause of deathFunding or business
“Sponsor decision”
Life of this trial
- Registered 5 months before it started.
- Ran for about 3 years 9 months before it stopped.
- 1,150 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Anthos Therapeutics, Inc.
- Sponsor type
- Industry
- Conditions
- Venous Thromboembolism; Deep Venous Thrombosis; Pulmonary Embolism
- Interventions
- Abelacimab; Apixaban
- Participants
- 1,150
- Sites
- 209
- Countries
- Australia, Austria, Canada, China, Czechia, France, Germany, Hungary, Ireland, Italy, Japan, Latvia and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.